Atea Projects Over $700M in Annual U.S. Revenue with HCV Launch

Atea Pharmaceuticals has outlined its potential to achieve over $700 million in peak annual U.S. net revenue, with a strategic focus on the launch of its HCV treatment in mid-2028.